Skip to content

Evaluation of efficacy of oxycodone combined with butorphanol tartrate in patient-controlled intravenous analgesia after secondary cesarean section.

Evaluation of efficacy of oxycodone combined with butorphanol tartrate in patient-controlled intravenous analgesia after secondary cesarean section.

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800015076
Enrollment
Unknown
Registered
2018-03-06
Start date
2018-04-01
Completion date
Unknown
Last updated
2018-03-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pain in post-ceserean section

Interventions

oxycodone +oxycodone combined with butorphanol group:oxycodone iv injection+oxycodone combined with butorphanol PCIA
butorphanol+butorphanol group:butorphanol iv injection +butorphanol PCIA

Sponsors

The first affiliated hospital of Nanjing Medical University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 45 Years

Inclusion criteria

Inclusion criteria: 1. Single parturient women undergoing selective secondary ceserean section; 2. Patients aged 20-45 years old, Height 150-175cm, BMI 18-35, ASA I-II.

Exclusion criteria

Exclusion criteria: (1) Allergic to oxycodone or any of the drugs used in this study; (2) Severe cardiopulmonary dysfunction and renal insufficiency; (3) Long-term opioid drug users; (4) Contraindication of intraspinal anesthesia; (5) History of nausea and vomiting; (6) Women with mental illness and language communication difficulties.

Design outcomes

Primary

MeasureTime frame
visual analogue scale;traction response;analgesic satisfaction;PCIA times in wards;analgesic dose consumption;

Secondary

MeasureTime frame
colostrum time;lactation times;

Countries

China

Contacts

Public ContactWei Zhu

The First Affiliated Hospital of Nanjing Medical University

zhuweijsph@163.com+86 13505182820

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026